ALS symptom progression brings challenges, but for columnist Dagmar Munn, the key to living well with the disease is to be ...

The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ALS in the EU.

The first patient has been dosed in an open-label Phase 1/2 clinical trial of AMT-162, uniQure's one-time gene therapy for ...

Rozebalamin, an ultra-high dose vitamin B12 treatment, was approved in Japan to slow disease progression in people with ALS.

A Texas Children’s Hospital investigator won a $2.4 million NIH grant for ALS and other neurodegenerative disease research.

After her late husband's diagnosis anniversary, columnist Juliet Taylor reflects on how grief became a heavy burden and a ...

The Scott-Morgan Foundation is launching a joint initiative that aims to use AI technologies to help improve communication ...

RNS60 is an experimental therapy designed to boost the formation of new mitochondria and restore energy production in nerve ...

People with ALS can benefit from voice-generating artificial intelligence, improving their quality of life, columnist Kristin Neva writes.

Neuvivo has filed an application with the U.S. Food and Drug Administration (FDA) requesting the approval of its ...

NeuroSense plans to apply to Canada’s regulators for early marketing approval of the oral therapy, supported by a Phase 2b ...

Avextra plans a Phase 2 trial in Italy to test a cannabis-based oral medicine to ease symptoms in ALS and other ...